Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.

ABSTRACT: Antibody cancer therapies rely on systemically accessible targets and suitable antibodies that exert a functional activity or deliver a payload to the tumor site. Here, we present proof-of-principle of in vivo selection of human antibodies in tumor-bearing mice that identified a tumor-specific antibody able to deliver a payload and unveils the target antigen. By using an ex vivo enrichment process against freshly disaggregated tumors to purge the repertoire, in combination with in vivo biopanning at optimized phage circulation time, we have identified a human domain antibody capable of mediating selective localization of phage to human prostate cancer xenografts. Affinity chromatography followed by mass spectrometry analysis showed that the antibody recognizes the proteasome activator comp

SUBMITTER: Sanchez-Martin D 

PROVIDER: S-EPMC3752212 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature